Updates

September 24, 2020September 24, 2020
Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient

A first patient has been dosed in a Phase 1 clinical trial investigating the small molecule inhibitor EPI-7386 as a treatment for metastatic castration-resistant ... Read more
September 22, 2020September 22, 2020
Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

Lynparza (olaparib) has been recommended for approval in the European Union to treat men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA1 and BRCA2, two ... Read more
September 17, 2020September 17, 2020
NCI Grant to Probe Link Between Prostate Cancer and Fatty Cells in Bone Marrow

A five-year grant of more than $2 million from the National Cancer Institute (NCI) will support research investigating the link between prostate cancer cells and ... Read more
September 10, 2020September 10, 2020
NIH Grants Dartmouth Team $2.5M to Develop Device for Detecting Cancer Cells

A research team at the Thayer School of Engineering at Dartmouth received a $2.5 million grant to develop and test a device meant to help ... Read more
September 8, 2020September 8, 2020
IPCR Launches Exercise Video Series for Prostate Cancer Patients

The Institute for Prostate Cancer Research (IPCR), a collaborative effort between the Fred Hutchinson Cancer Research Center and UW Medicine, has launched a video ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

September 12, 2017September 12, 2017

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

News

Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European ... Read more

Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient

Lynparza’s Approval Favored in EU for mCRPC Patients with BRCA Mutations

NCI Grant to Probe Link Between Prostate Cancer and Fatty Cells in Bone Marrow

NIH Grants Dartmouth Team $2.5M to Develop Device for Detecting Cancer Cells

IPCR Launches Exercise Video Series for Prostate Cancer Patients

‘Eat It to Beat It’ Challenge to Honor Prostate Cancer Awareness Month

FDA Approves Blood Test That Can Identify Cancers Eligible for Targeted Therapies

Tolmar Affirms Full Supply of Eligard for Palliative Treatment of Prostate Cancer

Google AI System Outperforms General Pathologists in Grading Prostate Cancers, Study Finds

Dosing Begins in Trial of PET Imaging Agent to Detect Prostate Cancer’s Return

Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer

Subscribe to our mailing list

Collaboration Seeks to Reduce Prostate Cancer Disparities in African Americans

New Guidelines for Care of Advanced Prostate Cancer Released

New Risk Calculator May Help Men With High PSA Decide on Having Prostate Biopsy

First AI-based Cancer Detection Application Slated for UK Rollout

Laser Focal Therapy Effective, Causes Few Side Effects, 10-Year Trial Data Shows

University of Colorado Launches PreView Medical for PC Diagnosis, Treatment

Vaccine Shows Promise in Advanced Prostate Cancer, Proof-of-Concept Study Shows

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Ipatasertib Combo Fares Well in Early Results of IPATential150 Phase 3 Study

Relugolix Granted FDA Priority Review as New Treatment Type

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

Veyonda Aids Radiation Therapy in Reaching Distant Lesions in Late-stage Cancer Trial

Cancer DNA Levels in Blood Can Predict Treatment Responses

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

U.K. Study to Examine Genetic Screening for Large Prostate Cancer Population

NHS England Offers Xtandi, Zytiga to New PC Patients During COVID-19 Pandemic

ADT May Protect Prostate Cancer Patients from COVID-19, Study Suggests

Updated Guidelines Recommend Rubraca for Some Prostate Cancer Patients

Rubraca Receives Conditional FDA Approval for metastatic CRPC Patients with BRCA Mutations

FDA Approves Lynparza for mCRPC Patients with Mutations in DNA Repair Genes

Erleada Add-on Significantly Extends Survival in Non-metastatic CRPC, SPARTAN Analysis Shows

Yervoy Can Benefit Certain mCRPC Patients with Few Mutations in Tumors, Trial Finds

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

Cancer Vaccine Plus Opdivo Showing Promise in Advanced Prostate Cancer Trial

Gene Variant Seen to Promote Castration-resistant Disease in Whites

Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest

Guidelines for Radiation Therapy with COVID-19 Urge Less Treatment

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

Urine Biomarkers Can Be Used to Develop Test for Prostate Cancer, Study Finds

Pin It on Pinterest